Kimmtrak (Tebentafusp)

Tebentafusp is a bispecific fusion protein that binds the gp100 peptide‑HLA complex on melanoma cells and CD3 on T‑cells. This dual binding redirects and activates T‑cells, forming an immunological synapse that leads to tumor‑cell killing through perforin, granzymes, and cytokine release.

The dosing regimen for Kimmtrak is determined by the prescribing oncologist based on the patient’s clinical condition, body weight, and HLA status. Specific dose amounts and infusion schedules are set individually and are not publicly disclosed.

Safety data for Tebentafusp in pregnant or nursing women are limited. The product is classified as contraindicated in pregnancy and breastfeeding until more information is available, and it should only be used if the potential benefit justifies the potential risk.

To request Kimmtrak, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and import documentation.

Kimmtrak differs from checkpoint inhibitors such as pembrolizumab by directly retargeting T‑cells to a melanoma‑specific antigen (gp100) rather than releasing inhibitory pathways. This mechanism can produce rapid tumor responses but carries a distinct safety profile, including cytokine release syndrome.

Kimmtrak must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Proper cold‑chain handling is required during transport and before infusion.

Kimmtrak is given as an intravenous infusion in a clinical setting. The infusion is performed by qualified healthcare professionals, with monitoring before, during, and after the dose to manage any infusion‑related reactions.

The most critical adverse events include severe cytokine release syndrome, capillary leak syndrome, neurotoxicity (such as seizures or encephalopathy), and serious cardiac events. Early detection and prompt medical intervention are essential to mitigate these risks.

Kimmtrak should not be used in patients with known hypersensitivity to tebentafusp or any of its excipients, in individuals receiving live vaccines, or in those with uncontrolled cardiac or severe hepatic conditions unless the treating physician determines that benefits outweigh risks.